AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1.-9. (Canceled)

10. (Currently Amended) A process for the viral inactivation or viral depletion of a protein preparation, which comprises subjecting a stabilized protein preparation ~~as claimed in claim 1~~ to a heat treatment at 40 to 95 °C for a period of 5 to 50 hours, wherein the stabilized protein preparation is an aqueous protein solution containing no antithrombin III, which comprises more than 1.5 g/ml of one or more saccharides as a mixture with more than 0.8 mol/l each of two or more amino acids chosen from arginine, lysine, histidine, phenylalanine, tryptophan, tyrosine, aspartic acid and its salts, and glutamic acid and its salts, wherein one of said amino acids is glutamate.

11. (Currently Amended) A process for the viral inactivation or viral depletion of a protein preparation, which comprises subjecting a stabilized protein preparation ~~as claimed in claim 1~~ to viral depletion by means of filtration, wherein the stabilized protein preparation is an aqueous protein solution containing no antithrombin III, which comprises more than 1.5 g/ml of one or more saccharides as a mixture with more than 0.8 mol/l each of two or more amino acids chosen from arginine, lysine, histidine, phenylalanine, tryptophan, tyrosine, aspartic acid and its salts, and glutamic acid and its salts, wherein one of said amino acids is glutamate.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

12. (Currently Amended) A process for the viral inactivation or viral depletion of a protein preparation, which comprises subjecting a stabilized protein preparation ~~as claimed in claim 1~~ to a viral depletion by means of centrifugation, wherein the stabilized protein preparation is an aqueous protein solution containing no antithrombin III, which comprises more than 1.5 g/ml of one or more saccharides as a mixture with more than 0.8 mol/l each of two or more amino acids chosen from arginine, lysine, histidine, phenylalanine, tryptophan, tyrosine, aspartic acid and its salts, and glutamic acid and its salts, wherein one of said amino acids is glutamate.

13. (Currently Amended) A process for the viral inactivation or viral depletion of a protein preparation, which comprises subjecting a stabilized protein preparation ~~as claimed in claim 1~~ to a treatment with detergents or bactericidal or virucidal agents, wherein the stabilized protein preparation is an aqueous protein solution containing no antithrombin III, which comprises more than 1.5 g/ml of one or more saccharides as a mixture with more than 0.8 mol/l each of two or more amino acids chosen from arginine, lysine, histidine, phenylalanine, tryptophan, tyrosine, aspartic acid and its salts, and glutamic acid and its salts, wherein one of said amino acids is glutamate.

14.-16. (Canceled)

17. (New) The process of claim 10, wherein the stabilized protein preparation further comprises glycine, glutamine, or glycine and glutamine together.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

18. (New) The process of claim 10, wherein the stabilized protein preparation further comprises a soluble calcium salt in an amount of at least 0.5 mmol/l.

19. (New) The process of claim 10, wherein the stabilized protein preparation comprises 1.75 g/ml sucrose, 1.5 mol/l sodium glutamate, and 1.5 mol/l arginine.

20. (New) The process of claim 10, wherein the stabilized protein is one or more blood clotting factors chosen from FII, FV, FVII and FVIIa, FVIII, FIX, FX, FXII and their combination preparations, the von Willebrand factor (vWF), FVIII/vWF, or one or more proteins chosen from albumins, immunoglobulins, protease inhibitors, ∝-2-antiplasmin, ∝-1-antitrypsin, protein C, activated protein C, protein S, protein Z, tissue factor pathway inhibitor (TFPI), fibrinogen, fibronectin and plasminogen.

21. (New) The process of claim 10, wherein the saccharide is a monosaccharide, a disaccharide or an oligosaccharide.

22. (New) The process of claim 10, wherein the stabilized protein preparation further comprises a soluble calcium salt in an amount of at least 1.0 mmol/l.

23. (New) The process of claim 11, wherein the stabilized protein preparation further comprises glycine, glutamine, or glycine and glutamine together.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

24. (New) The process of claim 11, wherein the stabilized protein preparation further comprises a soluble calcium salt in an amount of at least 0.5 mmol/l.

25. (New) The process of claim 11, wherein the stabilized protein preparation comprises 1.75 g/ml sucrose, 1.5 mol/l sodium glutamate, and 1.5 mol/l arginine.

26. (New) The process of claim 11, wherein the stabilized protein is one or more blood clotting factors chosen from FII, FV, FVII and FVIIa, FVIII, FIX, FX, FXII and their combination preparations, the von Willebrand factor (vWF), FVIII/vWF, or one or more proteins chosen from albumins, immunoglobulins, protease inhibitors, ∝-2-antiplasmin, ∝-1-antitrypsin, protein C, activated protein C, protein S, protein Z, tissue factor pathway inhibitor (TFPI), fibrinogen, fibronectin and plasminogen.

27. (New) The process of claim 11, wherein the saccharide is a monosaccharide, a disaccharide or an oligosaccharide.

28. (New) The process of claim 11, wherein the stabilized protein preparation further comprises a soluble calcium salt in an amount of at least 1.0 mmol/l.

29. (New) The process of claim 12, wherein the stabilized protein preparation further comprises glycine, glutamine, or glycine and glutamine together.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

30. (New) The process of claim 12, wherein the stabilized protein preparation further comprises a soluble calcium salt in an amount of at least 0.5 mmol/l.

31. (New) The process of claim 12, wherein the stabilized protein preparation comprises 1.75 g/ml sucrose, 1.5 mol/l sodium glutamate, and 1.5 mol/l arginine.

32. (New) The process of claim 12, wherein the stabilized protein is one or more blood clotting factors chosen from FII, FV, FVII and FVIIa, FVIII, FIX, FX, FXII and their combination preparations, the von Willebrand factor (vWF), FVIII/vWF, or one or more proteins chosen from albumins, immunoglobulins, protease inhibitors, ∝-2-antiplasmin, ∝-1-antitrypsin, protein C, activated protein C, protein S, protein Z, tissue factor pathway inhibitor (TFPI), fibrinogen, fibronectin and plasminogen.

33. (New) The process of claim 12, wherein the saccharide is a monosaccharide, a disaccharide or an oligosaccharide.

34. (New) The process of claim 12, wherein the stabilized protein preparation further comprises a soluble calcium salt in an amount of at least 1.0 mmol/l.

35. (New) The process of claim 13, wherein the stabilized protein preparation further comprises glycine, glutamine, or glycine and glutamine together.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

36. (New) The process of claim 13, wherein the stabilized protein preparation further comprises a soluble calcium salt in an amount of at least 0.5 mmol/l.

37. (New) The process of claim 13, wherein the stabilized protein preparation comprises 1.75 g/ml sucrose, 1.5 mol/l sodium glutamate, and 1.5 mol/l arginine.

38. (New) The process of claim 13, wherein the stabilized protein is one or more blood clotting factors chosen from FII, FV, FVII and FVIIa, FVIII, FIX, FX, FXII and their combination preparations, the von Willebrand factor (vWF), FVIII/vWF, or one or more proteins chosen from albumins, immunoglobulins, protease inhibitors, ∝-2-antiplasmin, ∝-1-antitrypsin, protein C, activated protein C, protein S, protein Z, tissue factor pathway inhibitor (TFPI), fibrinogen, fibronectin and plasminogen.

39. (New) The process of claim 13, wherein the saccharide is a monosaccharide, a disaccharide or an oligosaccharide.

40. (New) The process of claim 13, wherein the stabilized protein preparation further comprises a soluble calcium salt in an amount of at least 1.0 mmol/l.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com